New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 17, 2012
07:45 EDTVIVOMeridian Bioscience price target raised to $24 from $22 at RW Baird
Baird raised its price target on Meridian Bioscience following meeting with management. The firm believes investors sentiment is low but feels comfortable with guidance and management strategy for growth. Shares are Outperform rated.
News For VIVO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2015
08:02 EDTVIVOMeridian Bioscience reaffirms FY15 EPS view 85c-91c, consensus 86c
Subscribe for More Information
08:02 EDTVIVOMeridian Bioscience reports Q3 EPS 22c, consensus 22c
Reports Q3 revenue $48.2M, consensus $48.6M.
July 20, 2015
09:26 EDTVIVOMeridican says illumigene receives FDA clearance
Meridian Bioscience announced that it has received FDA clearance for two new molecular assays for the detection of Herpes Simplex Virus Type 1 and Type 2, to be run on its illumigene molecular platform. The illumigene HSV 1&2 assays, launched earlier this year in Europe, are now available immediately in the U.S.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use